Literature DB >> 10380879

Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis.

E Stickeler1, F Kittrell, D Medina, S M Berget.   

Abstract

Using a mouse model of mammary gland development and tumorigenesis we examined changes in both alternative splicing and splicing factors in multiple stages of mammary cancer. The emphasis was on the SR family of splicing factors known to influence alternative splicing in a wide variety of genes, and on alternative splicing of the pre-mRNA encoding CD44, for which alternative splicing has been implicated as important in a number of human cancers, including breast cancer. We observed step-wise increases in expression of individual SR proteins and alternative splicing of CD44 mRNA during mammary gland tumorigenesis. Individual preneoplasias differed as to their expression patterns for SR proteins, often expressing only a sub-set of the family. In contrast, tumors demonstrated a complex pattern of SR expression. Little difference was observed between neoplasias and their metastases. Alternative splicing of CD44 also changed through the disease paradigm such that tumors produced RNA containing a mixture of variable exons, whereas preneoplasias exhibited a more restricted exon inclusion pattern. In contrast, other standard splicing factors changed little in either concentration or splicing pattern in the same cells. These data suggest alterations in relative concentrations of specific splicing factors during early preneoplasia that become more pronounced during tumor formation. Given the ability of SR proteins to affect alternative processing decisions, our results suggest that a number of pre-mRNAs may undergo changes in alternative splicing during the early and intermediate stages of mammary cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10380879     DOI: 10.1038/sj.onc.1202671

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4.

Authors:  E Stickeler; S D Fraser; A Honig; A L Chen; S M Berget; T A Cooper
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

2.  Regulation of breast cancer-induced bone lesions by β-catenin protein signaling.

Authors:  Yan Chen; Heidi Y Shi; Stuart R Stock; Paula H Stern; Ming Zhang
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

Review 3.  Systems approaches to molecular cancer diagnostics.

Authors:  Shuyi Ma; Cory C Funk; Nathan D Price
Journal:  Discov Med       Date:  2010-12       Impact factor: 2.970

4.  Multifactorial interplay controls the splicing profile of Alu-derived exons.

Authors:  Oren Ram; Schraga Schwartz; Gil Ast
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

5.  Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones.

Authors:  Xiang-Yang Zhong; Jian-Hua Ding; Joseph A Adams; Gourisankar Ghosh; Xiang-Dong Fu
Journal:  Genes Dev       Date:  2009-02-15       Impact factor: 11.361

6.  The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression.

Authors:  Vânia Gonçalves; Paulo Matos; Peter Jordan
Journal:  RNA       Date:  2008-10-24       Impact factor: 4.942

7.  Transformer 2β (Tra2β/SFRS10) positively regulates the progression of NSCLC via promoting cell proliferation.

Authors:  Lili Ji; Tingting Ni; Yanbo Shen; Qun Xue; Yifei Liu; Buyou Chen; Xuefan Cui; Liting Lv; Xiafei Yu; Yuan Cui; Xiaoning Lu; Jie Chen; Guoxin Mao; Yuchan Wang
Journal:  J Mol Histol       Date:  2014-06-21       Impact factor: 2.611

Review 8.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

Review 9.  Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Authors:  Emma S Rennel; Steven J Harper; David O Bates
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

Review 10.  Regulation of splicing by SR proteins and SR protein-specific kinases.

Authors:  Zhihong Zhou; Xiang-Dong Fu
Journal:  Chromosoma       Date:  2013-03-24       Impact factor: 4.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.